The archive · Bio & Materials · Financial decision · 2016
Unity Biotechnology raises $116M with Bezos backing to build anti-aging drugs
Anti-aging startup Unity Biotechnology bet clearing senescent cells could become a drug pipeline; its $116M Series B, backed by Bezos, arrived in October 2016.
Unity Biotechnology
What the business is
Unity Biotechnology develops drugs that clear senescent cells — aging cells linked to chronic disease — by repurposing apoptosis-inducing drug candidates from cancer research into a standard drug-development pipeline.
Starting capital：$116M Series B announced around 2016-10-27, with backing Bloomberg credited to Jeff Bezos.
How it started
By late 2016 Unity Biotechnology was, in the description of a detailed commenter on its own funding thread, arguably the most mainstream of the startups targeting the clearance of senescent cells as a rejuvenation therapy — a company characterized by high-profile relationships with noted laboratories, venture groups and big names in the field. The approach rested on research going back decades: senescent cells accumulate with age and, even at about one percent of a tissue, secrete signals that disrupt structure and behavior, while remaining few enough to clear without major disruption.
What happened
The company's $116M Series B financing was announced around 2016-10-27, timed with its latest published research on senescent cells in atherosclerosis pathology, a pattern one commenter approvingly noted. Bloomberg's coverage credited the round with backing from Jeff Bezos. The discussion framed Unity as following the standard playbook for a hot drug company — repurposing apoptosis-inducing drug candidates to clear senescent cells — while skeptics argued that senescent cells are an evolved anti-cancer mechanism, so clearing them could trade aging for cancer, and that investors might really be betting on a cancer-adjacent market rather than rejuvenation.
No ending yet — it is still running.
Background
On 2016-10-27 Bloomberg reported that an anti-aging startup had raised $116 million with backing from Jeff Bezos, and the report's URL named Fidelity alongside him. The company was Unity Biotechnology, which announced the raise as a $116 million Series B financing. The story drew 208 points and 243 comments on Hacker News that day, where much of the discussion turned on whether aging could be treated as a disease at all.
Unity's bet was that aging could be attacked as a normal drug-development problem. As detailed in the discussion around its press release, the company was the most mainstream of the startups trying to clear senescent cells — aged cells that accumulate and disrupt tissue — and it planned a standard pipeline that repurposed apoptosis-inducing drug candidates from cancer research. A quoted company position shared in the thread held that success meant people living free of a variety of chronic diseases, not people living to 150 years.
The round was timed with the company's latest research on senescent cells in atherosclerosis pathology, and supporters read it as a landmark for rejuvenation funding. Skeptics argued that clearing senescent cells could trade aging for cancer, and that investors might really be wagering on a cancer-adjacent market. The sources record no therapy in the clinic yet.
What has to be true
- Unity treated aging like any other indication, using a standard biotech pipeline of repurposed oncology drugs instead of a fountain-of-youth pitch.
- The science had momentum in 2016: senescent-cell clearance had shown life-extension and tissue-repair data in mice, cited in the funding thread.
- A $116M Series B with Bezos backing told the market that credible investors would fund rejuvenation science, not just supplements.
- Skeptics framed the tradeoff: senescent cells are an evolved anti-cancer mechanism, so the same bet could be read as a cancer bet in disguise.
What can be applied
An unproven field can raise like a proven one when packaged as an ordinary drug developer — Unity's repurposed pipeline let blue-chip backers put $116M behind senescent-cell science.
Aftermath
As of 2016-10-27, the date this entry's sources cover, Unity Biotechnology had just announced the $116M Series B and was in the building stage of a standard drug-development pipeline: repurposing apoptosis-inducing drug candidates to clear senescent cells, with published atherosclerosis research accompanying the raise. The sources record no clinical product and no later milestones for the company.
Sources
- Anti-Aging Startup Raises $116M With Bezos Backing
- Anti-Aging Startup Raises $116M With Bezos Backing — Hacker News discussion
spotted an error? The archive wants to know.
Your turn
You just read one. Describe what you are building, and see who is betting on the same thing.
Free account · 3 free questions · no card